Investing.com -- Shares of Tempest Therapeutics Inc (NASDAQ: TPST) climbed 5.3% following the announcement that the European Medicines Agency (EMA) has granted Orphan Drug Designation to its cancer ...

The multiple regulatory designations were granted following strong positive results from a global randomized Phase 1b/2 study in first-line HCC demonstrating superior outcomes for amezalpat ...

The purpose of the pharma package is to revise the current rules on medicines to make them more accessible to patients while ...

Tevimbra is currently approved in the EU as a treatment for gastric cancer, esophageal squamous cell cancer and small cell ...

AstraZeneca (AZN) stock in focus as its antibody drug Imfinzi gains EU panel support for treating muscle-invasive bladder ...

Adding Blenrep to standard therapy prolonged progression-free survival in patients with relapsed or refractory multiple ...

The autologous immunotherapy consists of the patient’s own T cells engineered to express a chimeric antigen receptor that ...

German drugmaker Bayer on Friday won an endorsement by the European Medicines Agency to extend the intervals between shots of ...

Bayer BAYRY announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) ...

SpringWorks Therapeutics (NASDAQ:SWTX) said that an advisory panel of the European Medicines Agency (EMA), endorsed Mirdametinib, as a treatment for patients with neurofibromatosis type 1, aged 2 ...